articleEMBO Molecular MedicineMar 3, 2016GOLD OA

sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers

MSMarc Suárez‐CalvetGKGernot KleinbergerMÁMiguel Ángel Araque CaballeroMBMatthias BrendelARAxel Rominger

German Center for Neurodegenerative Diseases · Ludwig-Maximilians-Universität München · +16 more institutions

PubMed
Indexed incrossrefdoajpubmed

Abstract

TREM2 is an innate immune receptor expressed on the surface of microglia. Loss-of-function mutations of TREM2 are associated with increased risk of Alzheimer's disease (AD). TREM2 is a type-1 protein with an ectodomain that is proteolytically cleaved and released into the extracellular space as a soluble variant (sTREM2), which can be measured in the cerebrospinal fluid (CSF). In this cross-sectional multicenter study, we investigated whether CSF levels of sTREM2 are changed during the clinical course of AD, and in cognitively normal individuals with suspected non-AD pathology (SNAP). CSF sTREM2 levels were higher in mild cognitive impairment due to AD than in all other AD groups and controls. SNAP individuals…

Citation impact

526
total citations
FWCI
21.97
Percentile
100%
References
55
Citations per year

Authors

27

Topics & keywords

Topics
Keywords
  • Microglia
  • Cerebrospinal fluid
  • Biomarker
  • Alzheimer's disease
  • Disease
  • Stage (stratigraphy)
  • Medicine
  • Immunology
No related works found for this paper.

Funding